Tankiewicz-Kwedlo Anna, Lobacz Tomasz, Kozlowski Leszek, Czartoryska-Arlukowicz Bogumila, Koda Mariusz, Pawlak Krystyna, Czarnomysy Robert, Borkowska Magdalena Joanna, Pawlak Dariusz
Department of Pharmacodynamics, Medical University of Bialystok, Mickiewicza 2C, 15-222 Bialystok, Poland.
M. Skłodowska-Curie Bialystok Oncology Center, Ogrodowa 12, 15-027 Bialystok, Poland.
Cancers (Basel). 2023 Dec 26;16(1):120. doi: 10.3390/cancers16010120.
ONCOBREAST-TEST is a diagnostic and therapeutic procedure that is part of the comprehensive care of a patient with breast cancer.: Chemosensitivity of cancer cells was assessed using the MTT test, morphological assessment of cells, LDH activity in the culture medium, and flow cytometry technique (apoptosis, proliferation, CD24, CD44, GATA3, cytokeratin, Ki-67). Diagnostic tools included panels of simple tests which could be used to accurately predict the chemosensitivity of tumor cells previously isolated from a patient, even before actual chemotherapy. The proposed procedure allows for a simple (based on MTT results, cell morphology, LDH concentration), minimally invasive, quick, and accurate assessment of the sensitivity of breast cancer cells to the drugs used and, to select the most effective treatment plan as part of personalized therapy. In a patient with NOS G3, the most promising therapy will be docetaxel with cyclophosphamide and in the case of a patient with NOS G1, paclitaxel alone and in combination with trastuzumab. The implementation of such a procedure would undoubtedly increase the effectiveness of chemotherapy, reduce side effects by excluding drugs that are ineffective before using them, protect the patient's health, and shorten the treatment time, bringing economic and social benefits.
ONCOBREAST-TEST是一种诊断和治疗程序，是乳腺癌患者综合护理的一部分。使用MTT试验评估癌细胞的化学敏感性、细胞形态学评估、培养基中的乳酸脱氢酶（LDH）活性以及流式细胞术技术（凋亡、增殖、CD24、CD44、GATA3、细胞角蛋白、Ki-67）。诊断工具包括一系列简单测试，这些测试甚至可在实际化疗之前用于准确预测先前从患者体内分离出的肿瘤细胞的化学敏感性。所提议的程序能够基于MTT结果、细胞形态、LDH浓度进行简单、微创、快速且准确的乳腺癌细胞对所用药物敏感性评估，并作为个性化治疗的一部分选择最有效的治疗方案。对于非特殊类型（NOS）G3级患者，最有前景的治疗方案是多西他赛联合环磷酰胺；对于NOS G1级患者，最有前景的治疗方案是单独使用紫杉醇以及联合曲妥珠单抗。实施这样的程序无疑会提高化疗效果，通过在使用前排除无效药物来减少副作用，保护患者健康，并缩短治疗时间，带来经济和社会效益。
